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Approximately 100,000 primary and metastatic brain tumor patients/year in the US survive
long enough (>6 months) to experience radiation-induced brain injury. Prior to 1970, the
human brain was thought to be highly radioresistant; the acute CNS syndrome occurs after
single doses >30 Gy; white matter necrosis occurs at fractionated doses >60 Gy. Although
white matter necrosis is uncommon with modern techniques, functional deﬁcits, includ-
ing progressive impairments in memory, attention, and executive function have become
important, because they have profound effects on quality of life. Preclinical studies have
provided valuable insights into the pathogenesis of radiation-induced cognitive impairment.
Given its central role in memory and neurogenesis, the majority of these studies have
focused on the hippocampus. Irradiating pediatric and young adult rodent brains leads to
several hippocampal changes including neuroinﬂammation and a marked reduction in neu-
rogenesis. These data have been interpreted to suggest that shielding the hippocampus
will prevent clinical radiation-induced cognitive impairment. However, this interpretation
may be overly simplistic. Studies using older rodents, that more closely match the adult
human brain tumor population, indicate that, unlike pediatric and young adult rats, older
rats fail to show a radiation-induced decrease in neurogenesis or a loss of mature neurons.
Nevertheless, older rats still exhibit cognitive impairment. This occurs in the absence of
demyelination and/or white matter necrosis similar to what is observed clinically, suggest-
ing that more subtle molecular, cellular and/or microanatomic modiﬁcations are involved in
this radiation-induced brain injury. Given that radiation-induced cognitive impairment likely
reﬂects damage to both hippocampal- and non-hippocampal-dependent domains, there is
a critical need to investigate themicroanatomic and functional effects of radiation in various
brain regions as well as their integration at clinically relevant doses and schedules. Recently
developed techniques in neuroscience and neuroimaging provide not only an opportunity
to accomplish this, but they also offer the opportunity to identify new biomarkers and new
targets for interventions to prevent or ameliorate these late effects.
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RADIATION-INDUCED BRAIN INJURY
Radiation-induced brain injury is often observed after fraction-
ated partial or whole brain irradiation (fWBI); the syndrome
includes both anatomic and functional deﬁcits. Based on the time
of clinical expression (Figure 1), radiation-induced brain injury
is described in terms of acute, early delayed, and late delayed
injury (Toﬁlon and Fike, 2000). Acute brain injury, expressed
in days to weeks after irradiation, is rare with current radia-
tion therapy techniques. Early delayed brain injury occurs 1–6
months post-irradiation and can involve transient demyelina-
tion with somnolence. Although both of these early injuries can
result in severe reactions, they are normally reversible and resolve
spontaneously. In contrast, late delayed brain injury, character-
ized histopathologically by vascular abnormalities, demyelination,
and ultimately white matter necrosis (Schultheiss and Stephens,
1992), is usually observed >6 months post-irradiation; these late
delayed injuries have been viewed as irreversible and progressive.
Classically, late radiation-induced brain injury was viewed as due
solely to a reduction in the proliferating capacity of glial (van
den Maazen et al., 1993) or vascular endothelial (Calvo et al.,
1988) cells. The loss of either of these cell types could ulti-
mately produce white matter necrosis, but the loss of glial cells
was thought to cause necrosis earlier than the loss of vascular
endothelial cells. However, there is a growing awareness that
patients receiving fWBI can have signiﬁcant cognitive impair-
ment at >6 months post-irradiation even when they do not have
detectable anatomic abnormalities (Sundgren andCao, 2009). The
impact of cognitive impairment on a patient’s quality of life (QOL)
is now recognized as second only to survival in clinical trials
(Frost and Sloan, 2002).
THE VASCULAR HYPOTHESIS OF LATE DELAYED
RADIATION-INDUCED BRAIN INJURY
Proponents of the vascular hypothesis of late radiation-induced
brain injury argue that vascular damage leads to ischemia and sec-
ondarily to white matter necrosis. In support of this hypothesis,
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FIGURE 1 | Symptoms and timeline for the development of
radiation-induced brain injury in patients treated with fWBI.
a large amount of data has described radiation-induced vascular
structural changes, including vessel wall thickening, vessel dila-
tion, and endothelial cell nuclear enlargement (Calvo et al., 1988;
Reinhold et al., 1990; Schultheiss and Stephens, 1992). Quantita-
tive studies in irradiated rat brains have also demonstrated time-
and dose-dependent reductions in the number of endothelial cell
nuclei, blood vessel density, and blood vessel length (Reinhold
et al., 1990; Brown et al., 2007). Moreover, white matter necro-
sis occurs in boron neutron capture studies where nearly all of
the radiation damage is to the vasculature (Morris et al., 1996).
A recent study in rodents has shown that capillary rarefaction
and tissue hypoxia increased in all regions of the hippocampus
2 months after fWBI (Warrington et al., 2011a). Paradoxically,
these investigators also showed that low ambient oxygen levels
were able to restore the brain microvascular density (Warring-
ton et al., 2011a,b) and reverse cognitive impairment (Warrington
et al., 2012). Other studies have shown that (i) alterations of the
blood–brain barrier (BBB) likely due to an imbalance in the lev-
els of the matrix metalloproteinase-2 and the metalloproteinase-2
tissue inhibitor, (ii) degradation of collagen type IV, an extracellu-
lar matrix component of the blood vessel basement membrane
(Lee et al., 2012), and (iii) changes in the mRNA and protein
expression of VEGF, Ang-1, Tie-2, and Ang-2 (Lee et al., 2011)
occur after clinically relevant single and fWBI doses. In a recent
study, primary cultured mouse fetal neural stem cells injected
into the tail vein after each of four 5 Gy fractions differenti-
ated into both brain endothelial cells and a variety of brain
cells; this restored the radiation-induced decrease in both cerebral
blood ﬂow and cognitive function (Joo et al., 2012). In contrast,
radiation-induced necrosis has been reported in the absence of
vascular changes (Schultheiss andStephens,1992). Also thePPARγ
agonist, pioglitazone, and theACE inhibitor, ramipril, that prevent
radiation-induced cognitive impairment in the rat (Zhao et al.,
2007a,b; Lee et al., 2012) do not reverse the reduction in vascular
density and length that occurs after fWBI (Brown, unpublished
data). Consequently, late radiation-induced brain injury cannot be
solely due to vascular damage despite the large amount of evidence
supporting this hypothesis.
THE PARENCHYMAL HYPOTHESIS OF
RADIATION-INDUCED BRAIN INJURY
OLIGODENDROCYTES
The parenchymal hypothesis of radiation-induced brain injury
initially focused on the oligodendrocyte that is required for the
formation of myelin sheaths. The key cell for generating mature
oligodendrocytes is the oligodendrocyte type-2 astrocyte (O-2A)
progenitor cell that loses its reproductive capacity after WBI in
the rat (Raff et al., 1983). It has been hypothesized that radiation-
induced loss of O-2A progenitor cells leads to a failure to replace
oligodendrocytes that ultimately results in demyelination and
white matter necrosis. Although the oligodendrocyte population
in young adult rats has been reported to be depleted within 24 h
after single WBI doses of ≥3 Gy and total fWBI doses of ≥4.5 Gy
(Bellinzona et al., 1996; Shinohara et al., 1997; Kurita et al., 2001),
no change in the number of myelinated axons, the thickness of
myelin sheaths, and the cross-sectional area of myelinated axons
has been measured in cognitively impaired rats 12 months after
a total fWBI dose of 40 Gy delivered twice a week for 4 weeks to
middle-aged rats (Shi et al., 2009). Further, although the kinetics
of oligodendrocyte depletion is consistent with an early transient
demyelination, it is inconsistent with the late onset of white mat-
ter necrosis (Hornsey et al., 1981). Thus, the relationship between
radiation damage to oligodendrocytes and late radiation-induced
brain injury is still unclear.
ASTROCYTES
These cells constitute approximately 50% of the total glial cell
population in the brain and outnumber the neurons four to
one in higher mammals (Hansson, 1988). Once viewed as play-
ing a mere supportive role, astrocytes are now recognized as
a heterogeneous class of cells that perform diverse functions,
including modulation of synaptic transmission and secretion of
neurotrophic factors such as basic ﬁbroblast growth factor to
promote neurogenesis (Song et al., 2002; Seth and Koul, 2008).
Astrocytes have been shown to protect endothelial cells and
neurons from oxidative injury (Wilson, 1997). Also, juxtacrine
signaling between astrocytes and endothelial cells is critical for
generation and maintenance of a functional BBB, the vascular
structure that restricts entry of blood-borne elements into the
brain (Janzer and Raff, 1987). In response to injury, astrocytes
undergo proliferation, exhibit hypertrophic nuclei/cell bodies,
and show increased expression of glial ﬁbrillary acidic protein
(GFAP; Seifert et al., 2006; Yuan et al., 2006; Seth and Koul,
2008; Wilson et al., 2009; Zhou et al., 2011). These reactive
astrocytes secrete a host of pro-inﬂammatory mediators such as
cyclooxygenase (Cox)-2 and the intercellular adhesion molecule
(ICAM)-1, which may aid the inﬁltration of leukocytes into the
brain via BBB breakdown (Kyrkanides et al., 1999; Yuan et al.,
2006; Wilson et al., 2009; Zhou et al., 2011). Irradiating the rat
and mouse brain increases GFAP protein levels, both acutely
(24 h) and chronically (4–5 months; Chiang et al., 1993; Hong
et al., 1995). Conditioned medium from irradiated microglial cells
has been shown to induce astrogliosis which might contribute to
radiation-induced edema (Hwang et al., 2006). However, the exact
role of astrocytes in the overall pathogenesis of late radiation-
induced brain injury is still unclear, but they likely contribute by
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interacting with both vascular and other parenchymal elements in
the brain.
MICROGLIA
These immune cells represent about 12% of the total brain
cells (Gebicke-Haerter, 2001). In an uninjured brain, microglia
activelymonitor themicroenvironment to ensure that homeostasis
is maintained (Stoll and Jander, 1999). Microglia express neu-
rotrophins that selectively regulate (i) microglial function, (ii)
secretion of neurotrophic factors which promote neuronal sur-
vival, and (iii) proliferation (Elkabes et al., 1996). After injury,
microglia become activated, a process characterized by rounding
of the cell body, retraction of cell processes, proliferation, and
increased production of reactive oxygen species (ROS), cytokines,
and chemokines that mediate neuroinﬂammation (Stoll and Jan-
der, 1999; Gebicke-Haerter, 2001; Pocock and Liddle, 2001;
Kim and de Vellis, 2005).
Although microglial activation plays an important role in
phagocytosis of dead cells, sustained activation is thought to
contribute to a chronic inﬂammatory state in the brain (Gebicke-
Haerter, 2001; Joo et al., 2012). Tissue culture studies have demon-
strated that irradiating activated microglia leads to a marked
increase in expression of the pro-inﬂammatory genes TNFα, IL-
1β, IL-6, and Cox-2, and the chemokines, MCP-1 and ICAM-1
(Chiang et al., 1993; Kyrkanides et al., 1999, 2002; Hwang et al.,
2006; Lee et al., 2010). Rodent studies have also detected (i) an
increase in pro-inﬂammatory mediators within hours after irra-
diating the brain (Chiang et al., 1997; Kyrkanides et al., 2002; Lee
et al., 2010), and (ii) an increase in the percentage of activated
microglia in the brain during the latent period before the expres-
sion of late radiation-induced brain injury (Mildenberger et al.,
1990; Chiang et al., 1997; Monje et al., 2003). Rodent studies
and analysis of human brain tissue also suggest that microglial
activation may be associated with decreased hippocampal neuro-
genesis and cognitive function (Monje et al., 2002, 2007; Raber
et al., 2004). Anti-inﬂammatory agents such as ramipril and
indomethacin reduce the number of activatedmicroglia in the hip-
pocampus and/or perirhinal cortex andprevent radiation-induced
cognitive impairment in rodents (Monje et al., 2003; Lee et al.,
2012). However, the anti-inﬂammatory agent, L-158, 809, has
no effect on microglial activation, but still prevents radiation-
induced cognitive impairment (Robbins et al., 2009; Conner et al.,
2010). Finally, orthotopic injections of fetal neuronal stem cells
(NSC) that form new neurons without affecting the number of
activated microglia reverse radiation-induced cognitive impair-
ment in rodents (Acharya et al., 2009, 2011). Thus, the exact
role that activated microglia play in generating radiation-induced
brain injury, including cognitive impairment, is still an open
question.
NEURONS
Once considered a radioresistant population because they no
longer could divide, neurons have now been shown to respond
negatively to radiation. Studies have demonstrated radiation-
induced changes in hippocampal cellular activity (Gangloff and
Haley, 1960; Bassant and Court, 1978), synaptic efﬁciency/spike
generation (Bassant and Court, 1978; Pellmar and Lepinski,
1993), and neuronal gene expression (Noel et al., 1998; Rosi
et al., 2008). For example, irradiating the rodent brain with
single and fractionated doses produces changes in (i) neuronal
receptor expression of the immediate-early gene activity-regulated
cytoskeleton-associated protein (Arc) (Rosi et al., 2008), (ii) N-
methyl-D-aspartic acid (NMDA) receptor subunits (Shi et al.,
2006; Machida et al., 2010), (iii) glutaminergic transmission
(Rohde et al., 1979; Machida et al., 2010), and (iv) hippocam-
pal long-term potentiation (LTP; Snyder et al., 2001; Vlkolinsky
et al., 2008); all are important for synaptic plasticity and cognition.
Interestingly, these changes can occur in the absence of alterations
in the total number of mature neurons, the number of myelinated
axons, the thickness of myelin sheaths, and/or the cross-sectional
area of myelinated axons following fWBI (Shi et al., 2008). Thus,
subtle cellular and/ormolecular changes in the neurons themselves
or subtle changes in the association/communication between neu-
rons and astrocytes must play an as yet unidentiﬁed role in late
radiation-induced cognitive impairment.
THE DYNAMIC INTERACTIONS BETWEEN MULTIPLE CELL
TYPES HYPOTHESIS
Because no single cell or tissue associated with either the vas-
cular or parenchymal hypotheses can fully explain late delayed
radiation-induced brain injury, including cognitive impairment,
radiation-induced late effects are now hypothesized to occur due
to dynamic interactions between the multiple cell types in the
brain (Toﬁlon and Fike, 2000). Vascular endothelial cells, oligo-
dendrocytes, astrocytes, microglia, and neurons, are now viewed
not as passive bystanders that merely die from radiation dam-
age, but rather as active participants in an orchestrated response
to radiation injury that, theoretically, allows one to change the
response/outcome by intervening at numerous points in the
process to prevent or ameliorate the development of late radiation-
induced brain injury, including cognitive impairment. It is likely
that the successful unraveling of this puzzle will require the detec-
tion of subtle molecular, cellular, and microanatomic changes
in the brain that will clearly challenge basic science and clinical
investigators over the next decade.
COGNITIVE IMPAIRMENT IN BRAIN TUMOR SURVIVORS
AFTER fWBI
Radiation-induced cognitive impairment, including dementia, is
reported to occur in up to 50–90% of adult brain tumor patients
who survive >6 months post-irradiation (Crossen et al., 1994;
Giovagnoli and Boiardi, 1994; Johannesen et al., 2003; Meyers and
Brown, 2006). This cognitive impairment is marked by decreased
verbal memory, spatial memory, attention, and novel problem-
solving ability (Hochberg and Slotnick, 1980; Twijnstra et al.,
1987; Laukkanen et al., 1988; Roman and Sperduto, 1995). Nieder
et al. (1999) described signiﬁcant cognitive impairment in 49% of
patients at 2 years after treatment with fWBI; the incidence and
severity continued to rise over time (Figure 2). Chang et al. (2009)
documented a detectable cognitive impairment at 4 months after
fWBI compared to patients treated with radiosurgery. Moreover,
radiation-induced cognitive impairment occasionally progresses
to dementia where patients experience progressive memory loss,
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FIGURE 2 |The percentage of patients developing radiation-induced
cognitive impairment as a function of time after fWBI. Adapted from
Nieder et al. (1999).
ataxia, and urinary incontinence (Vigliani et al., 1999). Radiation-
induced dementia is a rare occurrence with fraction sizes <3 Gy
(DeAngelis et al., 1989; Klein et al., 2002). However, patients who
survive >2 years after fWBI have a continually increasing risk of
developing dementia over time (Scott et al., 1999). Importantly, all
of these late sequelae can be seen in the absence of radiographic
or clinical evidence of demyelination or white matter necrosis
(Dropcho, 1991; Shaw et al., 2006).
In spite of the relative rarity of progressing to frank dementia,
radiation-induced cognitive impairment has signiﬁcant effects on
QOL. The majority of >6 month survivors of partial or whole
brain irradiation have a symptom cluster consisting of fatigue,
changes in mood, and cognitive dysfunction (Gleason et al, 2007).
Results of neurocognitive testing in a phase III clinical trial (PCI
P120-9801) showed a signiﬁcant correlation between performance
on the Functional Assessment of Cancer Therapy-Brain Speciﬁc
(FACT-Br) test and a patient’s QOL as measured by the ability
to perform daily living activities (Li et al., 2008). In the Nieder
et al. (1999) study, 20% of patients treated with fWBI had a >10%
decline in Karnofsky Performance Status due to radiation-induced
cognitive impairment. Furthermore, brain tumor patients are sur-
viving longer due to improved radiation therapy techniques and
systemic therapies (Stupp et al., 2005; Cochran et al., 2012), so
the patient population experiencing radiation-induced cognitive
impairment is growing rapidly. Consequently, the search for (i)
biomarkers to identify patients who will/will not develop cog-
nitive impairment after fWBI and (ii) therapeutic strategies to
prevent/ameliorate radiation-induced cognitive impairment have
become very important.
ASSESSING RADIATION-INDUCED COGNITIVE
IMPAIRMENT IN THE CLINIC
The assessment of radiation-induced cognitive impairment in the
clinic has evolved over time. The mini-mental status examina-
tion (MMSE), a test for global cognitive function which has been
validated in other cognitive disorders, is relatively insensitive for
assessing radiation-induced cognitive impairment (Herman et al.,
2003; Kondziolka et al., 2005). The MMSE (i) does not avoid
memorized learning from repeat testing, (ii) is biased against
patients with lower educational backgrounds, and (iii) is rel-
atively insensitive to the subtle changes in function caused by
brain radiotherapy. To overcome these problems, recent cognitive
assessments have focused on the speciﬁc domains that are most
affected by brain irradiation (Klein et al., 2002; Shaw et al., 2006;
Chang et al., 2009).
Using intense neurocognitive assessments on primary and
metastatic brain tumor patients has been criticized because many
of their tumors recur leading to a general decline in health and
death. As such, patients are generally less willing to partici-
pate in intense cognitive testing as their health deteriorates, and
the utility of the results from those that do participate is ques-
tionable. Recently, RTOG study formulated a battery of tests
that focuses on the cognitive domains known to be affected
by brain irradiation, including memory, verbal ﬂuency, visual
motor speed, and executive function (Table 1); the estimated
time of completion is ∼30 min. In recent trials, this battery
of cognitive tests appears to overcome this major obstacle to
assessing radiation-induced cognitive impairment in brain tumor
patients.
EVALUATION OF PATIENT POPULATIONS FOR STUDYING
RADIATION-INDUCED COGNITIVE IMPAIRMENT
Several patient populations have been used to study radiation-
induced cognitive impairment. These populations include
(i) patients receiving prophylactic cranial irradiation (PCI) (Twi-
jnstra et al., 1987; Laukkanen et al., 1988; Grosshans et al., 2008),
(ii) patients with nasopharyngeal cancer (Cheung et al., 2000;
Hsiao et al., 2010), (iii) patientswith low-grade gliomas (Taphoorn
et al., 1994; Klein et al., 2002), (iv) patients with benign non-
parenchymal brain tumors (Gondi et al., 2011), and (v) patients
with primary (Klein et al., 2002) or metastatic brain tumors
(Nieder et al., 1999). The majority of these patients have (i) pri-
mary brain tumors treated with temozolomide and a variety
of radiation therapy techniques or (ii) metastatic brain tumors
treated with fWBI or radiosurgery. In general, about 50–70%
of these patients survive long enough (>6 months) to develop
radiation-induced cognitive impairment that affects their QOL.
Therefore, this is the population that presents the greatest chal-
lenge to the radiation oncologist. Nevertheless, it is also the
population with the greatest number of confounding factors (e.g.,
short life spans with declining health, tumor effects on brain
regions associated with cognition, prior treatment of systemic
disease with a variety of chemotherapeutic agents, concurrent
treatment with chemotherapy, steroids, and neurotrophic drugs)
that, by themselves, can affect cognition. Therefore, studying pop-
ulations, who receive fWBI but do not have fast growing tumors in
the brain, could provide important data on the role that radiation
damage plays in generating cognitive impairment in primary and
metastatic brain tumor patients.
SMALL CELL LUNG CANCER PATIENTS
The NCI published a study on 15 SCLC patients who were
long-term survivors after PCI and found that 12 of these
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Table 1 | Neurocognitive batteries used in modern prospective clinical trials.
Trial Intelligence Perception/psychomotor speed Memory Attention/executive function
EORTC Dutch adult reading test Line bisection test Working memory task Stroop color word test
Facial recognition test Visual verbal learning test Categoric word ﬂuency test
Judgment of line orientation Concept shifting test
Letter-digit substitution
RTOG 0614 COWA Trail-making A Hopkins verbal learning test Trail-making B
RTOG 0933 N/A N/A Hopkins verbal learning test N/A
One card learning test
International shopping list test
MDACC N/A N/A Hopkins verbal learning test N/A
CCOP 97100 COWA Trail-making A California verbal learning test Trail-making B
Rey Osterrieth complex ﬁgure
Digit span
exhibited abnormalities on neuropsychiatric testing, while seven
performed below the normal range on the MMSE test (John-
son et al., 1990). However, in a larger study of 69 SCLC
patients who received PCI, a substantial portion of the patients
exhibited cognitive impairments prior to PCI, and multivari-
ate analysis could not identify any signiﬁcant cognitive differ-
ences before and after PCI (Grosshans et al., 2008). Finally, in
another recent study, patients who received PCI had a detectable
decline in verbal memory just 6–8 weeks after completion of
PCI (Welzel et al., 2008). Thus, the radiation-induced cogni-
tive impairment data from SCLC patients who receive PCI
is confusing at best, probably because these patients received
chemotherapy and/or larger radiation fractions that are not typ-
ical of those used to treat primary and metastatic brain tumor
patients.
NASOPHARYNGEAL CANCER PATIENTS
Survivors of nasopharyngeal cancer offer another opportu-
nity to measure radiation-induced cognitive impairment in the
absence of a brain tumor. Patients treated for nasopharyn-
geal cancer routinely have high doses of radiation delivered
to the bilateral temporal lobes because of the need to treat
the superior retropharyngeal lymph nodes. These patients have
∼70% chance of long-term survival, and thus, the poten-
tial for development of radiation-induced cognitive impair-
ment, primarily due to damage to the temporal lobes. Che-
ung et al. (2000) reported that temporal lobe necrosis pre-
dicted a worsening of cognitive impairment in 50 irradiated
nasopharyngeal cancer patients who were followed longitudi-
nally with neuropsychological testing. Recently, Hsiao et al. (2010)
demonstrated that nasopharyngeal cancer patients treated with
intensity-modulated radiotherapy (IMRT) had a worse cogni-
tive outcome if >10% of their temporal lobe volume received
a total fractionated dose of >60 Gy than patients who received
<60 Gy.
LOW-GRADE GLIOMA PATIENTS
In a seminal publication by Klein et al. (2002), cognitive outcomes
of patients with low-grade glioma were compared to both patients
with indolent lymphomas that had no CNS disease and healthy
controls. The radiotherapy ﬁelds used in this study generally did
not include the entire brain. This analysis revealed that low-grade
gliomas, anti-epileptic medications, and radiotherapy could each
produce cognitive impairment; cognitionwasmost affected if frac-
tions>2Gywere used. Consequently, radiation-induced cognitive
data from low-grade glioma patients are also not likely to provide
information relevant to the majority of primary and metastatic
brain tumor patients. Shaw et al published results of a random-
ized trial in 200 adult low-grade glioma patients who received
either 50.4 Gy or 64.8 Gy at 1.8 Gy per fraction to partial brain
treatment ﬁelds (Shaw et al, 2002). This is the only known modern
primary brain tumor study in which patients were randomized to
receive low- versus high dose-radiation. There were no differences
in survival outcomes by dose. However, the incidence of radiation
necrosis (i.e., grade 3, 4 or 5 late brain toxicity) However, the 5-
year actuarial incidence of radiation necrosis (i.e., grade 3, 4 or 5
late brain toxicity) was 10% in patients receiving 64.8 Gy versus
5% for those given 50.4 Gy.
BENIGN NON-PARENCHYMAL BRAIN TUMOR PATIENTS
Arguably, the ideal populations for determining the radiation
tolerance of various brain regions are the patients with benign
non-parenchymal brain tumors such as meningiomas, pituitary
tumors, and schwannomas. These tumors generally do not affect
cognition and are not treated with chemotherapy. Patients with
these tumors have life expectancies long enough after fWBI to
experience radiation-induced cognitive impairment. Finally, the
results of these human studies could be compared to the results
of preclinical animal studies on radiation-induced brain injury,
including cognitive impairment, all of which have been performed
in animals that have no brain tumors or neurological diseases
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(Lamproglou et al., 1995; Yoneoka et al., 1999; Raber et al., 2004;
Rola et al., 2004). Such a comparison could greatly facilitate the
development of molecular, cellular, or imaging biomarkers of the
onset and progression of radiation-induced cognitive impairment
or interventions that could be successfully translated to the clinic.
Presently, the only published report on patients with benign non-
parenchymal brain tumors indicates that avoiding or lowering the
dose to the hippocampus will reduce radiation-induced cognitive
impairment (Gondi et al., 2011); the equivalent study has not been
performed in animals.
From the above discussion, it is distinctly possible that
the molecular, cellular, and microanatomic events that lead
to radiation-induced cognitive impairment are different for
SCLC, nasopharyngeal cancer, low-grade glioma, benign non-
parenchymal brain tumor, primary brain tumor, and metastatic
brain tumor patients. Consequently, (i) identifying biomarkers of
the onset and progression of radiation-induced cognitive impair-
ment and (ii) developing therapeutic strategies to prevent or
ameliorate radiation-induced cognitive impairment is likely to be
challenging for both basic scientists and physicians.
THE NEUROANATOMICAL TARGET THEORY OF
RADIATION-INDUCED COGNITIVE IMPAIRMENT
The target structures and dose thresholds for the development
of radiation-induced cognitive impairment are of current clinical
interest. Prior studies have suggested that partial brain irradia-
tion may not cause the same degree of cognitive impairment as
WBI (Armstrong et al., 1995; Torres et al., 2003). This observa-
tion could be explained by hypothesizing that there are speciﬁc
brain regions that lead to cognitive impairment. When the entire
brain is irradiated, no structure will be spared that could pro-
vide some normal or compensatory cognitive function. A recent
dose-volume histogram analysis of two prospective clinical tri-
als by Leyrer et al. (2011) indicates that it is not the dose to
the whole brain, but rather the dose to the hippocampus and
temporal lobes that predicts the subsequent radiation-induced
cognitive impairment. These authors proposed a neuroanatom-
ical target theory, which suggests that selective damage to certain
brain structures may be the cause of cognitive impairment after
radiotherapy. A corollary of such a theory is that selective avoid-
ance of these brain structures may be able to preserve cognitive
function. Recent advances in radiation therapy planning, includ-
ing the advent of stereotactic localization (Shrieve et al., 1994),
image guidance (Gutiérrez et al., 2007), IMRT (Barani et al., 2007b;
Gutiérrez et al., 2007), and proton beam radiotherapy (Rosen-
schold et al., 2011) have made it possible to selectively avoid brain
structures such as the hippocampus and temporal lobes to test
this theory.
NON-INVASIVE IMAGING BIOMARKERS OF
RADIATION-INDUCED COGNITIVE IMPAIRMENT
Currently, there are no validated biomarkers for determining who
will/will not develop radiation-induced brain injury, including
cognitive impairment, or who will/will not respond favorably
to therapies aimed at preventing or ameliorating these cognitive
deﬁcits. Radiation-induced late effects in the brain occur within
the closed cranial cavity. Therefore, non-invasive techniques are
needed to study this signiﬁcant side effect of brain tumor radio-
therapy. Given that radiation-induced cognitive impairment can
occur in the absence of radiographic evidence of gross anatomi-
cal changes, X-ray computed tomography (CT), T1/T2 magnetic
resonance imaging (MRI), and ultrasound techniques are not
likely to provide information relevant to the onset and progres-
sion of radiation-induced cognitive impairment. However, both
MRI and positron emission tomography (PET) have the ability
to interrogate metabolic, physiologic, and functional properties
of the brain. MRI utilizes magnetic ﬁelds to generate informa-
tion by exciting the protons in hydrogen atoms and monitoring
them as they relax. Depending on the pulse sequence, differ-
ences in the magnetic susceptibility properties of tissues can be
exploited to probe variousmolecular, cellular,microanatomic, and
physiologic properties of normal and tumor tissues. Magnetic res-
onance spectroscopy (MRS) utilizes anMR scanner to identify and
quantify metabolites that reﬂect both the cellular properties and
environmental conditions in speciﬁc regions of normal and tumor
tissues. PET utilizes radioligands that contain an atom that emits
a positron to interrogate the metabolic, receptor, physiologic, and
functional properties of normal and tumor tissue. Theoretically,
these three non-invasive techniques have the ability to identify
biomarkers of the onset and progression of radiation-induced
cognitive impairment.
NON-INVASIVE VASCULAR BIOMARKERS OF
RADIATION-INDUCED COGNITIVE IMPAIRMENT
Vascular injury has been hypothesized to play a critical role
in the development of late radiation-induced injury, includ-
ing radiation necrosis (Brown et al., 2005; Yuan et al., 2006).
Shortly after fWBI, vascular structure and function can be altered;
these alterations include blood vessel dilatation, endothelial cell
enlargement, capillary loss, and perivascular astrocyte hypertro-
phy which can lead to BBB disruption, increased permeability,
and edema. This acute vascular injury has the potential to be
detectable by MRI prior to the development of radiation-induced
demyelination and white matter necrosis (Reinhold et al., 1990;
Li et al., 2003).
Dynamic contrast-enhanced (DCE) MRI uses T1-weighted
imaging to quantitatively assess vascular permeability by repeat-
edly imaging the brain prior to and following a bolus i.v. injection
of a gadolinium contrast agent. By tracking the movement of the
contrast agent through the brain as a function of post-injection
time, and calculating the transfer constant, K trans, using a com-
partment model that describes the kinetics, the passive leakage
of the contrast agent from the intravascular to the extravascu-
lar extracellular space can be obtained (Tofts et al., 1999). High
K trans values indicate that the BBB is not intact; low K trans values
indicate that the BBB is intact. It has been suggested that these
increases in the BBB permeability after fWBI are the result of vas-
cular endothelial cell death (Li et al., 2003). Presently, there is no
evidence that DCE measured changes in BBB permeability are a
biomarker for the onset or progression of late radiation-induced
cognitive impairment.
FunctionalMRI (fMRI)measures the oxyhemoglobin todeoxy-
hemoglobin ratio in the brain to obtain an estimate of blood
ﬂow. Oxyhemoglobin is diamagnetic and does not generate an
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MR signal; deoxyhemoglobin is paramagnetic and emits a rel-
atively strong MR signal. If a brain region of interest (ROI) is
actively involved in a task, the area uses more oxygen, so the
deoxyhemoglobin level in the ROI increases. This increase in
deoxyhemoglobin generates an increased MR signal, but the signal
is out of phase with the normal brain signal, and thus, appears as a
decrease in the T2-weighted brain signal due to phase interference.
This decrease in the MR signal is called the blood oxygenation
level-dependent (BOLD) signal.
In a small study of childhood cancer survivors (n = 16), fMRI
was used to compare the activity in the visual cortex of childhood
survivors, unirradiated siblings, and unirradiated adults during a
visual task (Zou et al., 2005). Overall the timing of theBOLDsignal
triggered by the visual event was the same across all groups. How-
ever, the BOLD signal decreased in the childhood cancer survivors
to a value less than the baseline and stayed there for a prolonged
time before recovering. The survivors also had an overall reduc-
tion in the BOLD signal in the visual cortex when compared to
unirradiated siblings and adults. The number of voxels that had
an increase in the BOLD signal was greatest for those receiving
irradiation to both the brain and spinal cord. However, there was
no difference in the number of voxels that had an increase in
BOLD signal between those treated with chemotherapy and those
that were not. No similar study has been undertaken with either
adults or using a cognitive task. To date, we are unaware of a
BOLD study in unanesthetized pediatric or adult animal models.
Consequently, there is no direct evidence at this time that fMRI is
likely to identify a non-invasive biomarker of radiation-induced
cognitive impairment.
Arterial spin labeling (ASL) involves placing a pulsed or con-
tinuous RF ﬁeld on the carotid artery in the neck to align the spins
of the water protons in the blood (Detre et al., 2009). When the
blood leaves the RF ﬁeld, the proton spins return to their nor-
mal state producing an MR signal. The difference between the
brain MR signal, with and without the RF ﬁeld on, can be used
to calculate the blood ﬂow in a speciﬁc brain region before and
after fWBI. Increases or decreases in blood ﬂow are interpreted
as increases or decreases in the activity or function of a speciﬁc
brain region. By determining the blood ﬂow in various regions
associated with cognition before and after fWBI, it may be pos-
sible to obtain a non-invasive biomarker that predicts the onset
and/or progression of radiation-induced cognitive impairment.
However, there are no reports of a correlation between blood ﬂow
determined by ASL and radiation-induced cognitive impairment
at this time.
NON-INVASIVE PARENCHYMAL BIOMARKERS OF
RADIATION-INDUCED COGNITIVE IMPAIRMENT
Proton MRS is a non-invasive technique that uses an MR scanner
to (i) identify and quantify metabolites in the brain (Hoehn et al.,
2001; Gillies and Morse, 2005), (ii) differentiate radiation necro-
sis from brain tumor progression (Chong et al., 2002; Schlemmer
et al., 2002), and (iii) serve as a indicator of neurotoxicity fol-
lowing experimental (Yousem et al., 1992; Herynek et al., 2004)
and clinical brain irradiation (Esteve et al., 1998; Walecki et al.,
1999; Virta et al., 2000; Chan et al., 2001; Lee et al., 2004; Sundgren
et al., 2009). Brain metabolites that have been quantiﬁed include
choline/phosphocholine (Cho/pCho), creatine/phosphocreatine
(Cr/pCr), glutamate (Glu), glutamine (Gln), N-acetyl-aspartate
(NAA), myoinositol (mI), taurine (tau), and lactate. The concen-
tration of each of these metabolites can be quantiﬁed in voxels
as small as ∼15 mm3 in the rodent brain (Shi et al., 2011) with a
7T MR scanner and ∼0.7 cm3 in humans (Robbins et al., 2012)
with a 3T MR scanner. NAA and Glu are predominantly neuronal
markers; changes in their concentrations have been associated
with neuronal damage after fWBI (Shi et al., 2011) or neurolog-
ical diseases such as Alzheimer’s (Kaiser et al., 2005; den Heijer
et al., 2006). Gln and mI are predominantly glial cell mark-
ers; changes in their concentrations have been associated with
glial damage after fWBI (Pasantes-Morales et al., 2000; Shi et al.,
2011). Cho/pCho is associated with cell membrane synthesis;
concentration changes are associated with changes in cell pro-
liferation and inﬂammatory cell inﬁltration (Robbins et al., 2012).
Cr/pCr is a marker of energy metabolism; its concentration is
relatively constant throughout the brain before and after fWBI
(Sundgren and Cao, 2009).
Very little preclinical data are available on MRS detection of
metabolite changes in the normal brain following irradiation.
Using a 4.7TMR scanner,Herynek et al. (2004) observed decreases
in Cr and NAA at 8 and 12 months after bilateral Gamma Knife
irradiation with a dose of 35 Gy to the hippocampus of young
adult male rats; this dose resulted in severe functional and struc-
tural brain damage. Chan et al. (2009) used a 7T MR scanner to
determine signiﬁcant increases in Cho, Glu, tau, and lactate levels
at 12 months after the right half of young adult male rat brains
were irradiated with a single 28 Gy dose of 6 MV photons. These
changes in white matter were conﬁrmed histologically at post-
mortem. Finally, Atwood et al. (2007) used a 7T MR scanner to
demonstrate a potential relationship between radiation-induced
changes in NAA/tCr, Glu + Gln/tCr, and mI/tCr concentra-
tions in the rat brain after a 40 Gy total dose delivered in 5 Gy
fractions, twice per week for 4 weeks and cognitive impairment
measured by the novel object recognition test at 12 months after
fWBI. However, additional experiments using this rat model of
progressive radiation-induced cognitive impairment (Figure 3)
demonstrated that cognitive impairment occurred before changes
in these brain metabolites (Robbins et al., 2009). Thus, none of
the brain metabolite changes could serve as a biomarker (i) for
the onset/progression of radiation-induced cognitive impairment
or (ii) to assess the response to interventions that might pre-
vent/ameliorate radiation-induced cognitive impairment in this
rat model.
Clinically, MRS has been used to assess metabolite changes in
normal appearing white matter after fWBI (Esteve et al., 1998;
Walecki et al., 1999; Virta et al., 2000; Lee et al., 2004; Sund-
gren et al., 2009). Acute lymphoblastic leukemia survivors, treated
with intrathecal methotrexate and PCI, had decreasing NAA:Cr
and Cho:Cr ratios as a function of time (5.6–19 years) after
fWBI (Chan et al., 2001). In a prospective study of 11 adult
patientswith low-grade gliomasor benign tumors such as pituitary
adenomas and meningiomas treated with fWBI, MRS detected
signiﬁcant decreases in both the NAA:Cr and Cho:Cr ratios start-
ing 3 weeks after fWBI that persisted up to 6 months after fWBI
in normal appearing brain parenchyma (Sundgren et al., 2009).
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FIGURE 3 | Development of radiation-induced cognitive impairment as
a function of time after young adult male Fischer 344 X Brown Norway
rats were irradiated with a total 40 Gy dose of fWBI delivered as 5 Gy
fractions, twice/week for 4 weeks. Cognition was assessed using the
novel object recognition (NOR) task. The sham-irradiated group value is the
average of the NOR scores from unirradiated rats at all of the time points.
In this rat model, cognitive impairment is both progressive and not
signiﬁcantly different from sham-irradiated rats until ∼6 months after fWBI,
similar to what is observed in the clinic. ***P < 0.001.
Similar results have been obtained in several studies with glioma
patients (Esteve et al., 1998; Walecki et al., 1999; Virta et al., 2000;
Lee et al., 2004). Although the rodent data suggest that identi-
fying an MRS biomarker for the onset/progression of cognitive
impairment is unlikely, MRS may be still worthy of further study
in humans.
NON-INVASIVE DYNAMIC INTERACTION BIOMARKERS
OF RADIATION-INDUCED COGNITIVE IMPAIRMENT
Diffusion tensor imaging (DTI) assesses tissue microstructure by
measuring the diffusion of water molecules in three-dimensional
(3D) space (Le Bihan et al., 2001; Chan et al., 2009). The ability
of water molecules to diffuse in brain tissue is affected predom-
inantly by the white matter structure (i.e., the direction and
compactness of the myelinated ﬁbers in white matter tracts)
and the biochemical and biophysical properties of the myelin
in these tracts. Areas with little structure allow water to freely
diffuse in all directions; areas with a great amount of structure
will allow water to diffuse predominantly in one direction. The
fractional anisotropy (FA) index is commonly used to indicate
whether the water molecules in a particular region or tract are
free to move in all directions (spherical diffusion) or predom-
inantly in one direction (elliptical diffusion). FA values range
from 0 to 1; low FA values indicate spherical diffusion (little
structure), high FA values indicate elliptical diffusion (highly
structured). DTI images are normally color-coded to indicate the
primary direction of the diffusion in a particular brain region
(Figure 4).
FIGURE 4 | Diffusion tensor image of a rat brain color-coded to show
the predominant direction of diffusion in various brain regions; blue
indicates diffusion between anterior (A) and posterior (P), red
indicates flow between left (L) and right (R), and green indicates flow
between superior (S) and inferior (I). Adapted from Robbins et al. (2012).
Relative changes in the direction of the water diffusion in
3D space after irradiation are often used to distinguish demyeli-
nation from axonal injury; this interpretation is limited to
diffusion within white matter tracts. Differences in DTI parame-
ters are also found within cortical areas and represent alterations
in how water diffuses through the extracellular matrix, synap-
tic ﬁeld, and/or lightly myelinated/unmyelinated axons. DTI
indices can be compared on a voxel-by-voxel basis throughout
the brain, or by summing the voxels within each ROI and com-
paring the results between ROIs. DTI indices can also be used
to develop tractography maps of white matter bundles in the
brain (Johansen-Berg and Behrens, 2006). However, the appli-
cation of tractography to radiation-induced brain injury is still in
its infancy.
Diffusion tensor imaging has been used to assess early white
matter injury in both pediatric and adult patients treated with
fWBI (Khong et al., 2006; Qiu et al., 2007; Nagesh et al., 2008;
Dellani et al., 2008; Haris et al., 2008). In a recent prospective
DTI study, patients with high-grade gliomas (n = 19), low-grade
gliomas (n = 3), and benign tumors (n = 3) were imaged before,
during, and after fWBI (Nagesh et al., 2008). Analyses revealed
progressive DTI changes in the genu (anterior portion) and sple-
nium (posterior portion) of the corpus callosum. During the
ﬁrst 3 months after fWBI, dose-dependent demyelination was
detected predominantly in regions receiving high doses. However,
6months after fWBI, thisDTIdetectable demyelinationhad spread
to lower dose regions, suggesting that interventions might prevent
this spread if initiated when demyelination was ﬁrst detected at
3 months after fWBI (Nagesh et al., 2008).
In a cross-sectionalDTI study of survivors of childhoodmedul-
loblastoma and acute lymphoblastic leukemia, FA decreases in the
frontal and parietal lobes were associated with declines in intelli-
gence quotient after adjusting for the effects of age, dose, and time
after fWBI (Khong et al., 2006). The FA decreases were greater
in the frontal lobes than in the parietal lobes at the same radi-
ation dose (Qiu et al., 2007). In another study, FA values were
signiﬁcantly reduced in normal appearing cerebral white matter of
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the temporal lobe, hippocampus, and thalamus in adult survivors
treated with fWBI for acute lymphoblastic leukemia (Dellani et al.,
2008). In both of these studies, age-matched unirradiated controls
were used as the comparison group. Given that psychiatric and
health issues associated with a cancer diagnosis can inﬂuence cog-
nition, it is imperative that neurocognitive testing as well as FA
measurements be obtained prior to fWBI in future studies so that
each patient can serve as their own control.
In summary, DTI is a promising non-invasive technique that is
able to detect early changes in white matter integrity before radio-
graphic evidence of radiation-induced demyelination or white
matter necrosis occurs (Nagesh et al., 2008). These microanatomic
changes in normal appearingwhitemattermeasure properties that
likely result from dynamic interactions between irradiated oligo-
dendrocytes, astrocytes, and neurons. However, to correlate these
microanatomic changes to late delayed cognitive impairment will
require that each patient undergo both DTI and cognitive test-
ing prior to and after irradiation. Currently, there are ongoing
studies that obtain DTI and cognitive impairment measurements
prior to fWBI and over follow-up times as long as 18 months after
fWBI in an attempt to identify DTI biomarkers which predict the
onset and progression of radiation-induced cognitive impairment
(Chapman et al., 2012).
Another non-invasive measure of brain function can also be
obtained by quantifying the uptake of [18F]-2-deoxy-2-ﬂuoro-
D-glucose (FDG) during a cognitive task with PET. The FDG
uptake in a brain region is an indicator of the level of neurosy-
naptic activity in that region; the neurosynaptic activity depends
on the interaction among several cell types, e.g., oligodendrocytes
(myelin integrity), astrocytes (glutamine/glutamate transport),
and neurons (electrical pulse generation). When non-human pri-
mates (NHP) were given a total fWBI dose of 40 Gy delivered
twice a week for 4 weeks, both low- and high-load cognitive
function measured using a delayed match to sample (DMS) task
decreased during the 12 months after fWBI; high-load function
was impaired earlier than low-load function (Robbins et al., 2011).
When these NHP were injected i.v. with FDG 10 min prior to
a 40 min session on the DMS task and PET images acquired
after completion of the DMS task, there was a decrease in FDG
uptake in the cuneate and dorsal lateral prefrontal cortex and
an increase in FDG uptake in the thalamus and cerebellum at
9 months after fWBI compared to the FDG uptake in these ROIs
prior to fWBI (Figure 5). Thus, the brain regions usually involved
in the DMS task did not function normally 9 months after fWBI,
and increasing the activity of brain regions not usually involved
in the DMS task could not adequately compensate for this deﬁ-
ciency. Importantly, the DMS task and the PET technique used
in this NHP study can also be readily adapted for use in future
clinical trials.
PREVENTION/AMELIORATION OF RADIATION-INDUCED
BRAIN INJURY
A preponderance of evidence supports the hypothesis that late
radiation-induced brain injury, including cognitive impairment,
is driven by acute and chronic oxidative stress and inﬂamma-
tory responses (Robbins and Zhao, 2004; Zhao et al., 2007a).
In general, ionizing radiation produces its biological effects by,
either directly or indirectly, generating ROS that can modify
a cell’s molecular or functional phenotype. An acute dose-
dependent increase in ROS has been measured in cultures of
astrocytes, microglia, and neurons (Ramanan et al., 2008; Rob-
bins, unpublished data). In animals, stable end-products such
as lipid peroxides and nitrotyrosine have been used to quantify
the oxidative stress generated by exposure to ionizing radiation.
For example, irradiating one hemisphere of 8-day-old rat brains
or 10-day-old mouse brains with single 4–12 Gy doses of 4 MV
X-rays resulted in an acute time-dependent increase in nitrotyro-
sine in both the granular cell layer of the dentate gyrus (DG) and
the subventricular zone (Fukuda et al., 2004). An acute increase
in lipid peroxidation was also measured in the hippocampus of
adult male mice at 2 weeks after a single 10 Gy dose of WBI
(Limoli et al., 2004).
OXIDATIVE STRESS
Chronic oxidative stress is generally thought to result from an
inﬂammatory response where irradiation activates microglia and
causes immune cells to inﬁltrate the brain. These cells then gen-
erate ROS which in turn activate more microglia and activate
more immune cells that can maintain or increase the level of
oxidative stress. Interventions designed to reduce chronic oxida-
tive stress provide an opportunity to prevent or ameliorate late
radiation-induced brain injury, including cognitive impairment.
Oxidative stress is both difﬁcult to measure and difﬁcult to
interpret, particularly in long-term studies with animals. Conse-
quently, measures of the inﬂammatory response to the increase
in oxidative stress after irradiation are usually used as a surro-
gate. In tissue culture, irradiation of mouse microglial (BV-2)
cells signiﬁcantly increased activation of AP-1, NF-κB, and the
cAMP response element-binding protein, CREB, within the ﬁrst
24 h after irradiation (Ramanan et al., 2008; Lee et al., 2010).
Measurements of an acute inﬂammatory response have been
reported in rodent models including (i) upregulation of MCP-
1/CCL2 and MIP-2/CXCL2 mRNA levels (Kyrkanides et al., 2002;
Kalm et al., 2009; Lee et al., 2010), (ii) increased expression of
pro-inﬂammatory molecules such as TNFα, IL-1β, ICAM-1, and
Cox-2 (Ramanan et al., 2008; Lee et al., 2010), and (iii) activation
of pro-inﬂammatory transcription factors such as NFκB (Chi-
ang et al., 1997; Raju et al., 1999; Kyrkanides et al., 1999, 2002;
Lee et al., 2010). In a recent study, dose- and time-dependent
increases in transcript levels of inﬂammatory cytokines, activated
microglia, and activated endothelial cells were reported (Mora-
van et al., 2011). Finally, an acute inﬁltration of neutrophils and
a delayed increase in T cells, MHC II-positive cells, and CD-11c-
positive cells was observed in mice after single doses of ≥15 Gy
(Moravan et al., 2011).
CHRONIC INFLAMMATION
Measurements of a chronic inﬂammatory response to WBI and
fWBI in rodent models include (i) elevation of TNFα in mouse
brains up to 6 months post-irradiation (Hong et al., 1995), (ii)
regionally-speciﬁc up-regulation of TNFα, and IL-1β; TNFα lev-
els in cortex increased 57% more than in hippocampus, and IL-1β
levels in hippocampus increased 126% more than in cortex (Lee
et al., 2010), (iii) a marked increase in the number of activated
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FIGURE 5 | [18F]FDG-PET scans of cerebral glucose metabolism
9 months after fWBI of young adult male non-human primates.
Upper panel : post-fWBI < Pre-fWBI. Blue areas in the cuneate cortex
and prefrontal cortex exhibited less metabolic activity in scans obtained
9 months after fWBI than in scans obtained prior to fWBI. Lower panel :
post-fWBI > Pre-fWBI: the red areas in the cerebellum and thalamus
exhibited greater metabolic activity in scans obtained 9 months after fWBI
than in scans obtained prior to fWBI. The color bar is the degree of intensity
difference shown as a scale of t values with P < 0.001. Adapted from
Robbins et al. (2012).
microglia in the neurogenic zone of the DG (Monje et al., 2002),
(iv) increased expression of the CCR2 receptor in the mouse sub-
granular zone 9 months following high-LET brain irradiation
(Rola et al., 2005), and (v) persistent microglial activation in the
rodent brain (Schindler et al., 2008; Ramanan et al., 2009; Conner
et al., 2010). These results provide a rationale for the use of anti-
inﬂammatory-based interventions to prevent or ameliorate late
radiation-induced brain injury, including cognitive impairment.
NEUROGENESIS
In rodents, the hippocampus plays a major role in learning,
consolidation, and retrieval of information (Eichenbaum, 2001,
2004). Consequently, most rodent studies have focused on the
hippocampus to investigate radiation-induced brain injury. The
hippocampus consists of the DG, CA3, and CA1 regions; these
regions have been implicated in both rodent and human cog-
nition. NSCs in the DG are capable of both self-renewal and
generating neurons, astrocytes, and oligodendrocytes (Palmer
et al., 1997; Gage et al., 1998). Neurogenesis depends on the pres-
ence of a speciﬁc neurogenicmicroenvironmentwhere endothelial
cells and astrocytes can promote/regulate neurogenesis (Palmer
et al., 2000; Song et al., 2002). Irradiating the hippocampus results
in an increase in apoptosis in the subgranular zone of the DG
(Yazlovitskaya et al., 2006), a dose-dependent increased loss of
NSCs (Bellinzona et al., 1996), decreased proliferation of the
surviving NSC, and decreased NSC differentiation into neurons
(Snyder et al., 2001; Monje et al., 2002; Mizumatsu et al., 2003).
Young adult rats irradiated with a single dose of 10 Gy produced
only 3% of the new hippocampal neurons formed in unirradiated
rats (Monje et al., 2002). In contrast to neurogenesis, gliogenesis
appears to be preserved following irradiation (Monje et al., 2003).
Interestingly, all of these phenomena can be observed after doses
of ≤2 Gy that fail to produce demyelination and/or white matter
necrosis.
These reductions in hippocampal neurogenesis have also been
implicated in radiation-induced cognitive impairment. A decrease
in hippocampal neurogenesis has been correlated with deﬁcits
in hippocampal-dependent spatial learning and memory at 3
months after a single 5 Gy dose of WBI to 21-day-old mice
(Rola et al., 2004). When young adult mice received 10 Gy of
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focal irradiation to the hippocampus, a signiﬁcant decrease in
neurogenesis and cell proliferation was detected 3 months post-
irradiation; this reduction correlated to a decline in cognitive
function as assessed by the Barnes maze (Raber et al., 2004). Sim-
ilarly, both a reduction in neurogenesis and cognitive impairment
have been observed in young adult rats after fWBI (Yoneoka et al.,
1999; Shi et al., 2006; Lee et al., 2012). Thus, interventions that
(i) increase hippocampal neurogenesis, (ii) prevent the loss of
NSCs, or (iii) replace lost NSCs after irradiation may prevent
or ameliorate radiation-induced brain injury, including cognitive
impairment.
PRECLINICAL STUDIES OF THERAPEUTIC INTERVENTIONS
FOR RADIATION-INDUCED BRAIN INJURY
Although the exact mechanism(s) of radiation-induced brain
injury, including cognitive impairment is unclear, potential thera-
peutic strategies to prevent radiation-induced brain injury include
ROS scavengers, anti-inﬂammatory agents, and NSC transplanta-
tion. ROS scavengers have received little attention because they
are likely to protect brain tumors to the same extent as they
protect normal brain. Thus, most of the preclinical investiga-
tions have focused on anti-inﬂammatory agents and fetal NSC
transplantation.
Several rodent studies designed to prevent or amelio-
rate radiation-induced cognitive impairment have shown
promise using anti-inﬂammatory peroxisome proliferator-
activated (PPAR) agonists (Figure 6) that have been given to
patients for years to treat other syndromes (Derosa, 2010; McK-
eage and Keating, 2011). PPARα, δ, and γ are members of the
nuclear hormone receptor superfamily of ligand-activated tran-
scription factors that heterodimerize with the retinoid X receptor
to regulate gene expression (Blumberg and Evans, 1998). A grow-
ing body of evidence suggests that PPARs regulate inﬂammatory
signaling and are neuroprotective in a variety of CNS diseases
(Bright et al., 2008; Stahel et al., 2008; Ramanan et al., 2010).
Administering the PPARγ agonist, pioglitazone (Pio), to young
adult male rats starting 3 days prior to, during, and for 4 or 54
weeks after the completion of a total 40 Gy dose of fWBI delivered
twice a week for 4 weeks, prevented the radiation-induced cogni-
tive impairment measured 52 weeks after fWBI (Figure 6; Zhao
et al., 2007b). However, administration of Pio for 54 weeks start-
ing after the completion of fWBI did not signiﬁcantly modulate
radiation-induced cognitive impairment. Based on these data, a
phase I/II trial has been initiated to determine the dose of Pio that
can be given safely to brain tumor patients and obtain preliminary
data on the ability of Pio to prevent/ameliorate radiation-induced
cognitive impairment.
The renin–angiotensin system (RAS) has been classically
viewed as a complex systemic hormonal system. More recently,
several intra-organ RAS have been identiﬁed, including a brain
RAS (Davisson, 2003). The brain RAS is involved in mod-
ulation of the BBB, stress, memory, and cognition (Gard,
2002; McKinley et al., 2003). Both angiotensin-converting
enzyme inhibitors (ACEI) or angiotensin type-1 receptor block-
ers (ARB) have proven effective in treating experimental radiation
nephropathy (Moulder et al., 2003) and pneumopathy (Molteni
et al., 2000).
Chronic administration of the ACEI, ramipril to young adult
male F344 rats 2 weeks after stereotactic irradiation of the rat
brain with a single dose of 30 Gy was associated with a reduc-
tion in the severity of functional and histopathologic markers of
optic neuropathy assessed 6 months post-irradiation (Kim et al.,
2004). However, delaying the start of ramipril treatment to 4
weeks after irradiation resulted in a failure to reduce the sever-
ity of the radiation injury (Ryu et al., 2007). More recent studies
by Jenrow et al. (2010) have shown that ramipril produced modest
protection against WBI-induced decreases in neurogenesis, but
did not modulate radiation-induced neuroinﬂammation mea-
sured as microglial activation. In contrast, a recent study found
that ramipril was able to ameliorate both radiation-induced cog-
nitive impairment (Figure 6) andmicroglial activation in rats after
fWBI, but had no restorative effect on neurogenesis (Lee et al.,
2012). In the Jenrow et al. (2010) study, ramipril was started 24 h
after a single dose of WBI, whereas drug was administered before,
during, and after fWBI in the Lee et al. study. Thus, the timing
of the ramipril administration and/or the response after single or
fractionated doses may explain the different results obtained in the
two studies. At the present time, a phase I/II trial is being developed
to determine if ramipril can prevent/ameliorate radiation-induced
cognitive impairment in brain tumor patients.
Chronic administration of the ARB, L-158,809, to young adult
male rats for 3 days before, during, and for 28 or 54 weeks
after fWBI prevented the radiation-induced cognitive impairment
observed 26 and 52 weeks post-irradiation (Figure 6; Robbins
et al., 2009). Moreover, chronic administration of L-158,809 for 3
days before, during, and only 5 weeks post-irradiation prevented
the cognitive impairment observed 26 weeks post-irradiation
(Robbins et al., 2009). These radiation-induced cognitive impair-
ments occurred without any changes in brain metabolites or gross
histologic changes assessed at 28 and 54 weeks post-irradiation
(Robbins et al., 2009). Thus, both PPARγ agonists and ARBs may
prevent/ameliorate radiation-induced cognitive impairmentwhen
given for only a few weeks after fWBI.
In addition to drug therapeutics, there has been increased
interest in the use of various stem cell therapies to restore the
neurogenic niche and improve cognition. These studies are based
on the rationale that radiation results in a dramatic reduction
in hippocampal neurogenesis that has been linked to cognitive
impairment (Raber et al., 2004; Rola et al., 2004). Voluntary run-
ning has been shown to increase neurogenesis in the rodent
hippocampus with a concomitant improvement in spatial learn-
ing and memory after single WBI doses (Naylor et al., 2008;
Wong-Goodrich et al., 2010). Preclinical studies have also shown
that pretreatment with lithium or other Akt/glycogen synthase
kinase-3β (GSK-3β) inhibitors are neuroprotective, preventing
(i) apoptosis in the subgranular zone of the DG and (ii) the
radiation-induced decline in hippocampal dependent memory
in 1-week-old mice that received a single dose of 7 Gy WBI
(Yazlovitskaya et al., 2006; Thotala et al., 2008). Direct injection
of NSCs into rodent brains after WBI partially restores neuroge-
nesis and hippocampal-dependent cognitive function (Acharya
et al., 2009, 2011; Joo et al., 2012). Interestingly, these NSCs
not only differentiate into neurons, but also oligodendrocytes,
astrocytes, and endothelial cells that can alter the hippocampal
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FIGURE 6 | Both RAS inhibitors and PPAR agonists prevent
radiation-induced cognitive impairment in young adult male rats that
received a total 40 Gy dose of fWBI delivered in 5 Gy fractions,
twice/week for 4 weeks, and then tested for cognition at 6–12 months
post-irradiation using the NOR task. Rats were administered, (A) the ARB,
L-158,809 before, during, and for 54 weeks post-fWBI; tested at 52 weeks,
(B) the ACEI, ramipril, before, during, and for 28 weeks post-fWBI; tested at
26 weeks, (C) the PPARγ agonist, pioglitazone, before, during, and for 54
weeks post-fWBI; tested at 52 weeks, and (D) the PPARα agonist,
fenoﬁbrate, before, during, and for 29 weeks post-fWBI; tested at
26 weeks. *P < 0.05, **P < 0.01, ***P < 0.001 compared to sham-
irradiated rats.
microenvironment (Joo et al., 2012). However, the use of exercise
or NSC transplantation to prevent/ameliorate radiation-induced
cognitive impairment in humans will require considerably more
research before it can be translated to the clinic.
CLINICAL STUDIES OF THERAPEUTIC INTERVENTIONS FOR
RADIATION-INDUCED BRAIN INJURY
One strategy for the prevention of radiation-induced cognitive
impairment in the clinic involves avoidance of brain structures
associated with cognitive function. Recent clinical trials have
focused on avoiding the regions of adult neurogenesis, including
the hippocampus and neural stem cell niche in the periventricular
regions. These trials have been met with criticism because NSCs,
like the stem cells found in other organ systems, are thought
to be exquisitely sensitive to ionizing radiation; complete elim-
ination of the NSCs in rodents occurs in the range of 2–6 Gy
(Barani et al., 2007a,b; Gutiérrez et al., 2007). In addition, other
brain regions such as the dorsal lateral prefrontal cortex play a
major role in human cognition, unlike in the rodent where the
hippocampus dominates. Preliminary data from the University
of Wisconsin suggest that patients receiving doses ≥7.2 Gy to
the bilateral hippocampi have worse cognitive function as mea-
sured by the Wechsler Memory test (Gondi et al., 2011). The
RTOG is currently conducting a single arm prospective trial using
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hippocampal-sparing IMRT. This trial intends to enroll 100
patients and assess cognitive outcomes compared to historical
controls. While technology has evolved to potentially allow for
hippocampal sparing, it may be premature to conduct large-scale
prospective clinical trials for hippocampal sparing when brain
regions other than the hippocampus are involved in cognition, and
the dose that eliminates neurogenesis in the human hippocampus
is unknown.
There are no known preventive medications for radiation-
induced cognitive impairment in humans, although several
pharmacologic agents have been evaluated for symptomatic man-
agement. The ﬁrst category of drugs assessed were the psy-
chostimulants. There are several reports (DeLong et al., 1992;
Weitzner et al., 1995; Meyers et al., 1998) using methylphenidate to
treat radiation-induced fatigue and cognitive impairment. Using
methylphenidate doses of 10-30mg twice daily in adults, fatigue
is reduced and cognitive function is enhanced. Another class of
drugs are the reversible cholinesterase inhibitors such as donepezil
(Aricept®). The Wake Forest Community Clinical Oncology Pro-
gramResearchBase recently completed a clinical trial randomizing
200 brain tumor patients who survived at least 6months after frac-
tionated partial- or whole-brain irradiation to either placebo or
donepezil 10mg/day for 6months. The randomized trialwas based
on results of a previously completed phase II open-label study
where 10 mg/day of donepezil showed signiﬁcant improvement in
energy level, mood, and cognitive function in an identical patient
population or irradiated brain tumor survivors (Shaw et al., 2006).
In the phase II study, fatigue, mood, and cognition were also mea-
sured following a 6-weekwashout period from the discontinuation
of donepezil. Worsening in all three domains was observed.
The RTOG has just completed a randomized placebo con-
trolled trial evaluating the efﬁcacy of memantine, an NMDA
receptor antagonist that has been shown to be effective in vascu-
lar dementia. It is hypothesized that blocking this receptor blocks
ischemia-induced NMDA excitation and thus, may be neuropro-
tective if radiation-induced ischemia occurs after fWBI. In this
study, patients were treated with either memantine or placebo
during and for 24 weeks after fWBI. The primary endpoint of
the study involves memory deﬁcits measured by the Hopkins
Verbal Learning Test at 24 weeks. The trial has 554 patients
and is now closed to accrual; to date, there are no preliminary
results.
Finally, clinical trials of other potential pharmacologicalmedia-
tors of cognitive function are being developed based on preclinical
data suggesting that anti-inﬂammatory agents can prevent or ame-
liorate radiation-induced cognitive function. A phase I/II trial
of Pio given to brain tumor patients before, during, and after
fWBI has been initiated, and phase I/II trials of ramipril and an
ARB are being developed. Although it is simplistic to think that
one approach or one pharmacological intervention will eliminate
radiation-induced brain injury, including cognitive impairment
for every patient whose brain is treated with ionizing radiation,
it is highly likely that signiﬁcant inroads will be made to pre-
vent/ameliorate this increasingly important side effect of brain
irradiation over the next decade.
SUMMARY
Recent improvements in systemic treatments and radiation ther-
apy techniques have resulted in over 100,000 patients in the
US each year surviving long enough after fWBI to develop
radiation-induced brain injury, including cognitive impairment
that signiﬁcantly affects their QOL. Although modern radiation
therapy techniques have eliminated acute and early delayed brain
injury as well as most late demyelination and white matter necro-
sis, dynamic interactions between multiple cell types in the brain
appear to be responsible for generating late radiation-induced cog-
nitive impairment that affects the QOL of most survivors. It is also
likely that the radiation-induced cognitive impairment measured
in long term survivors of SCLC, nasopharyngeal cancer, low-
grade glioma, non-parenchymal tumors, primary brain tumors,
and metastatic brain tumors is different because their diseases are
treated differently.
Preclinical studies suggest that anti-inﬂammatory drugs may
prevent/ameliorate radiation-induced cognitive impairment by
intervening at various points in the inﬂammatory response to
both irradiation and the presence of a brain tumor. However to
date, the most effective preclinical treatments have to be given
prior to, during, and continuously after irradiation. Given that
∼50% of all brain tumor patients die in <6 months after fWBI,
and only 50–90% of those that survive >6 months after fWBI
develop radiation-induced cognitive impairment, it is impera-
tive that non-invasive biomarkers be identiﬁed that predict who
will/will not develop radiation-induced cognitive impairment, and
who will/will not respond to interventions, so that treatments will
be limited only to those that will ultimately beneﬁt from them.
Although the early clinical trials have had only modest success in
modulating radiation-induced cognitive impairment, the future
looks promising because our knowledge of how radiation-induced
brain injury develops, how it can be non-invasively detected, and
how it can be treated has improved considerably over the past
decade.
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